Clinical trial
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial…
NCT00407758 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00407758 |
|---|---|
| Title | Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of Enzastaurin (Lilly IND # 60, 933) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin hydrochloride |
| Enrollment | 28 |
| Start date | Nov 1, 2006 |
| Primary completion | Aug 1, 2016 |
| First posted | Dec 5, 2006 |
| Last update posted | Mar 20, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: